Samantha Du’s Zai Lab sets its ambitions sky high, looking to raise $750M to fuel its licensing business model

Looking to capitalize on a bustling Chinese drug market, upstart biotechs like Samantha Du’s Zai Lab have made a killing in-licensing foreign molecules as well as developing their own homegrown assets. Now, with even more growth in mind, Zai Lab has offered up a healthy chunk of shares on the…